Retatrutide before & after.

Retatrutide before and after: actual weight-loss results

The 12 mg group in TRIUMPH-1 lost an average 70.3 lb, or 28.3% of starting weight, at 80 weeks under adherence-based assumptions. The analysis that included treatment interruptions and stopping gave 62.1 lb, or 25.0%. Both figures belong to the same study; they answer slightly different questions. [1] [2]

These are group estimates from trial participants with obesity or qualifying overweight, without diabetes. They are not verified transformations of customers using the products shown on this site. Pound conversions use illustrative starting weights; they are not individual patient outcomes.

Six-month and one-year results: 24 and 48 weeks

Weight continued to decline between the two main assessments in the phase 2 obesity trial. The 338 participants were assigned to different weekly amounts; the 4 mg and 8 mg rows combine two starting-dose schedules. [3]

Phase 2 trial averages. *Calculated as 250 lb × the reported percentage, rounded to one decimal; these are illustrative pound equivalents, not observed individual outcomes. [3]

The 12 mg group's average changed by 6.7 percentage points between weeks 24 and 48. Applied to the same hypothetical 250 lb starting weight, that is another 16.75 lb. It is additional loss measured against the original weight, rather than 6.7% of the already lower weight.

A six-week or eight-week course cannot be assigned the 48-week result. The trial also does not establish a fixed number of pounds lost every week. Early treatment included dose escalation, and an individual's progress need not follow a straight line.

80-week results: 4 mg, 9 mg and 12 mg

TRIUMPH-1 tested three maintenance amounts in 2,339 participants. Its published treatment-regimen results include what happened when people interrupted or stopped treatment. The table also gives the separately reported adherence-based estimates. [2] [1]

The headline 28.3% and the published 25.0% should not be combined into a claimed range of individual outcomes. They are alternative statistical estimates. A person can lose less than either average, more than either average or stop because treatment is unsuitable.

The adherence-based estimate asks what might be achieved under continued assigned treatment without prohibited weight-management treatment. The broader estimate incorporates treatment changes. Neither removes the need to consider tolerability; a higher assigned amount is not automatically the best practical option for everyone.

How many participants lost 25%, 30% or more?

An average and a success threshold answer different questions. In TRIUMPH-1's adherence-based analysis of the 12 mg group, the estimated proportions reaching larger reductions at 80 weeks were: [1]

*Calculated pound equivalents. The threshold percentages describe how much weight was lost; the middle column describes the estimated share of participants who reached that threshold.

Fewer than half reached the 30% threshold even in this analysis. Someone losing 20% could still have a large, meaningful change without appearing in any of these three rows. The headline average is therefore a reference point, not a minimum result that every participant should reach.

Before and after at 200, 250 and 300 pounds

Starting weight × percentage lost = pounds lost. Subtract that amount from starting weight to obtain the calculated after-weight. The same percentage creates a larger pound change from a heavier starting point.

Arithmetic scenarios, not expected individual results. Pound amounts are calculated from the percentages shown. The 28.3% column represents the size of the TRIUMPH-1 adherence-based average, not a promised target.

For a 250 lb start, reaching 200 lb requires 20% loss; reaching 175 lb requires 30%. Those are different goals even when both would produce a substantial appearance change. The table supplies the exact arithmetic without claiming how quickly either goal would be reached.

Pounds and kilograms also need consistent units. A 50 lb loss is approximately 22.7 kg. Treating “50” as the same amount in both systems would more than double the claimed change.

When do appetite and visible changes begin?

The first figure comes from a selected interview sample; the later time points are trial endpoints. These are not mandatory stages for every person. [8] [3] [2]

A change in appetite can be noticed before clothing fits differently. Conversely, feeling little immediate change does not identify a reason to jump ahead in a dose schedule. “How much by month one?” remains an individual question; the studies do not provide a guaranteed first-month pound total.

The trial programme used gradual increases. Its 80-week period therefore includes time below the final maintenance amount. Reading “12 mg at 80 weeks” as 12 mg from the first injection would misrepresent how the result was obtained. The weekly schedules show the actual stages.

Two-year results: the selected 104-week extension

The largest reported extension average was 30.3%, or 85.0 lb, at 104 weeks. This came from a selected continuation group initially assigned to 12 mg, with treatment adjusted to a maximum tolerated 9 or 12 mg during the extension. [1] [4]

The extension included 532 people with an original BMI of at least 35 who completed 80 weeks and tolerated their assigned treatment. It did not include every original participant. These requirements favour a group able to remain on treatment, so the two-year result should carry its selection criteria beside it.

It also cannot be read as a guarantee of another fixed number of pounds after week 80. The extension's starting characteristics and analysis differ from a simple subtraction of two headlines. For someone asking whether benefit must stop at one year, the finding supports the possibility of continued loss during longer supervised treatment.

Results with type 2 diabetes

TRIUMPH-2 · 80 WEEKS · ADHERENCE-BASED ESTIMATES

The placebo group lost 4.0%, or 9.3 lb. These results came from participants with both excess weight and type 2 diabetes. [5]

The lower average than the trial without diabetes does not mean a particular participant's response can be predicted from diagnosis alone. It does mean that the 28.3% headline should not be presented as the sole benchmark for every population. Starting health, medications, trial care and persistence all belong to the treatment context.

The 28.7% result: a separate knee-arthritis trial

TRIUMPH-4 reported 28.7%, or 71.2 lb, average weight loss with 12 mg at 68 weeks using the adherence-based analysis. The estimate including treatment changes was 23.7%, or 60.0 lb. Participants had excess weight and knee osteoarthritis. [6]

The 68-week result does not sit between the phase 2 48-week and TRIUMPH-1 80-week figures on one person's timeline. It is a separate population and study. Joining those endpoints into a single smooth “expected progress” curve would create a result that was never measured.

Knee-pain improvement is also distinct from a visible transformation. A participant can value improved walking even when their weight loss differs from the largest headline. The knee-pain section gives the actual symptom outcome.

What changes besides the number on the scale?

Weight loss includes changes in more than one tissue. A retatrutide DXA substudy in type 2 diabetes found lower total fat mass and some lean-mass loss. The relative lean loss was similar to that seen with other obesity treatments; the study did not demonstrate complete muscle preservation. [7]

Two people who each lose 40 lb can therefore finish with different waist shapes, strength and body-fat percentages. Starting muscle, fat distribution and the composition of the lost weight all affect the appearance change. A scale result cannot supply these details by itself.

The featured research vials have not been tested for these clinical outcomes. A certificate measuring identity or purity cannot verify a customer's weight loss or turn an unrelated transformation photograph into evidence for that batch. Product documentation and human results remain separate forms of information.

What trial participants actually described

QUALITATIVE EXIT INTERVIEWS · SELECTED SAMPLE

Interviews with 40 participants, including 36 who received retatrutide, described smaller portions, less frequent hunger, easier physical activity and changes in clothing size. Three retatrutide participants were frustrated by disappointing weight loss; some described social limitations related to side effects or changed eating habits. [8]

These accounts make the everyday experience more concrete without representing a success rate for everyone treated. Being pleased with the result and reaching an exact goal weight were separate outcomes. The interviews also did not independently test any commercially advertised vial or pen.

What happens after stopping retatrutide?

Some weight regain was observed four weeks after treatment stopped in the published fatty-liver substudy. That short follow-up does not establish how much people regain over six or twelve months. [9]

The dedicated maintenance study, TRIUMPH-6, uses an 80-week lead-in followed by 36 weeks comparing continued treatment, a lower amount and placebo. It remains underway, with completion planned for 2028. [10] Its design addresses a different question from simply extending successful treatment.

There is no reliable retatrutide-specific percentage of long-term weight loss retained after stopping in the sources reviewed here. A claim that a short course permanently resets weight, or that a particular small maintenance amount guarantees no regain, goes beyond the available results.